JAK抑制剂治疗脊柱关节炎附着点炎的临床疗效：一项文献综述
Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: A scoping literature review.
作者信息
Jubber Ameen, Tahir Hasan, Moorthy Arumugam
机构信息
Rheumatology Department, University Hospitals of Leicester, Leicester, UK.
Division of Medicine, University College London, London, UK.
出版信息
Musculoskeletal Care. 2023 Dec;21(4):1195-1203. doi: 10.1002/msc.1802. Epub 2023 Jul 28.
BACKGROUND
Enthesitis is a key feature of spondyloarthropathy (SpA). In recent years, JAK inhibitors have emerged as efficacious drugs in the landscape of advanced therapies for patients with SpA.
METHOD
The aim of this scoping literature review was to search the published literature for studies on JAK inhibitors and their effects on enthesitis in patients with SpA and evaluate the data and summarise the findings. The clinical trials reviewed used the Leeds Enthesitis Index, Spondyloarthritis Research Consortium of Canada Enthesitis Index, and Maastrich Ankylosing Spondylitis Enthesitis Score as outcome measures.
RESULTS
Tofacitinib, upadacitinib, and filgotinib had numerically greater reductions in the enthesitis scores when compared with placebo.
CONCLUSION
While the JAK inhibitors are therapeutic options for enthesitis in SpA, head-to-head studies are needed to compare the JAK inhibitors against the biological drugs (targeting TNF, IL-17, and IL-12/23) as well as studies showing the effects of JAK inhibitors on enthesitis imaging.
背景
附着点炎是脊柱关节炎（SpA）的关键特征。近年来，JAK抑制剂已成为SpA患者先进治疗方案中的有效药物。
方法
本综述性文献研究的目的是检索已发表的文献，查找关于JAK抑制剂及其对SpA患者附着点炎影响的研究，并评估数据和总结研究结果。所综述的临床试验使用利兹附着点炎指数、加拿大脊柱关节炎研究联盟附着点炎指数和马斯特里赫特强直性脊柱炎附着点炎评分作为结局指标。
结果
与安慰剂相比，托法替布、乌帕替尼和非戈替尼在附着点炎评分上有更大程度的降低。
结论
虽然JAK抑制剂是SpA中附着点炎的治疗选择，但仍需要进行直接比较的研究，以对比JAK抑制剂与生物药物（靶向TNF、IL-17和IL-12/23），以及展示JAK抑制剂对附着点炎影像学影响的研究。
Zotero 插件